Coronavirus Funding Opportunity Announcements

Released by the GCO Aug 2020

- Coronavirus (8/2/20)
- Coronavirus (8/3/20)
- Coronavirus (8/9/20)
- Coronavirus (8/13/20)
- Coronavirus (8/20/20)
- Coronavirus (8/23/20)
- Coronavirus (8/30/20)
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN. The first table of InfoEd funding opps is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office
Weekly NIH Funding Opportunities and Notices for July 31, 2020

Notice of Changes to Funding Opportunities

- Notice of NIDCR's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)" (NOT-DE-20-030) National Institute of Dental and Craniofacial Research

- NHLBI Withdraws Participation in NOT-MD-20-022 "Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations" (NOT-HL-20-802) National Heart, Lung, and Blood Institute

### SPIN Table 1 - Summary

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097474</td>
<td>WorkSafeBC</td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Program: Telehealth in Postmenopausal Patient Care

Program: Implementation of Telemedicine in Inflammatory Conditions: A Quality Improvement RFP

097532 Pfizer Pharmaceuticals 03-Sep-2020 100,000 USD

097533 Pfizer Pharmaceuticals 21-Sep-2020 250,000 USD

SPIN Table 2 - Detailed Information

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097467</td>
<td>Center for Sharing Public Health Services - Call for Proposals: Increasing the Body of Knowledge for Cross-Jurisdictional Sharing in Public Health – Small Grants Program</td>
<td>Johnson (Robert Wood) Foundation</td>
<td></td>
<td>11-Sep-2020</td>
<td>10,000 USD</td>
</tr>
</tbody>
</table>

Contact Name: Sydney McClendon
Contact Telephone: 855-476-3671
Contact Email: PHSharing@khi.org
Sponsor Website: Link to sponsor website
Program URL: Link to program URL

Synopsis:
The Center for Sharing Public Health Services (the “Center”) is offering small grants to support work on cross-jurisdictional sharing (CJS) arrangements designed to advance health equity by addressing social determinants of health (e.g., affordable housing, jobs with fair pay, quality education, affordable healthy food and public safety), the public health response to COVID-19, structural racism or other related issues.

2020 Specific Priorities - Impacts of COVID-19 - Request for Proposals

WorkSafeBC 31-Oct-2020 Not Specified

Contact Name: 
Contact Telephone: 604-244-6300
Contact Email: resquery@worksafebc.com
Sponsor Website: Link to sponsor website
The impacts of COVID-19 to BC workers, employers and the workers’ compensation system are broad and diverse. COVID-19 has changed the way work is done. Including where and how workers are expected to perform their job and how they interact with the workplace. New ways of working present new risks and challenges, while also providing new opportunities. Safe and durable return to work and recovery of injured workers requires new supports and changes to care delivery and return to work planning, while prevention approaches must adapt to new guidelines, workplaces and technologies. WorkSafeBC is interested in research projects to address both direct and indirect impacts arising from the COVID-19 pandemic unique to occupational health and safety, injured or ill worker recovery, and safe and sustainable return to work or stay-at-work.

**Competitive Grant**

**Program:** Telehealth in Postmenopausal Patient Care

**Pfizer Pharmaceuticals**

**Deadline Dates (ALL):** 03-Sep-2020

**Synopsis**

Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals intending to support programs focused on the education of healthcare practitioners (HCPs) to better leverage technology and utilize telehealth to optimize the hormone therapy benefit/risk discussion with postmenopausal patients as the need for telehealth to deliver patient care has increased during the COVID-19 pandemic. Individual projects requesting up to $100,000 will be considered.

**Competitive Grant**

**Program:** Implementation of Telemedicine in Inflammatory Conditions: A Quality Improvement RFP

**Pfizer Pharmaceuticals**

**Deadline Dates (ALL):** 21-Sep-2020

**Synopsis**

Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals intending to support programs focused on the education of healthcare practitioners (HCPs) to better leverage technology and utilize telehealth to optimize the hormone therapy benefit/risk discussion with postmenopausal patients as the need for telehealth to deliver patient care has increased during the COVID-19 pandemic. Individual projects requesting up to $250,000 will be considered.
Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals intending to support quality improvement for Healthcare Practitioners (HCPs) that treat RA, AD, and UC. Programs to help HCPs meet the ever-changing needs of patients during this challenging time will be supported. Individual projects requesting up to $250,000 will be considered.

SMARTS™ funding alerts are a service of InfoEd Global's SPIN™ funding opportunities
Dear Research Community,

Below is a COVID-19 funding opportunity recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
</table>

Contact Name: Ana Torres-Davis  
Contact Telephone: 202-272-2116  
Contact Email: atorresdavis@ncd.gov  
Sponsor Website: Link to sponsor website
The National Council on Disability (NCD) seeks proposals for a cooperative agreement to develop NCD’s annual progress report which will examine COVID-19’s broadscale impacts on people with disabilities in seven major areas: nondiscriminatory access to healthcare; the direct care workforce; group housing; education; employment; mental health; and communications.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN. The first table of InfoEd funding opps is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office
NIH Guide for Grants and Contracts (Web Version)

Weekly NIH Funding Opportunities and Notices for August 7, 2020

General Notices

- Request for Information (RFI): Fostering Innovative Research to Improve Mental Health Outcomes Among Minority and Health Disparities Populations
  (NOT-MH-20-073) National Institute of Mental Health

Notice of Changes to Funding Opportunities

- Notice of Correction to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" for Award Information about Clinical Trials
  (NOT-OD-20-149) National Institutes of Health

- Notice of Change to Funding Announcement (NOT-OD-20-048) by the Office of Research on Women's Health (ORWH), "Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)"
  (NOT-OD-20-156) Office of Research on Women's Health

- Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program
  (NOT-OD-20-157) National Institutes of Health I Office of Research on Women's Health

Notices of Special Interest

  (NOT-OD-20-159) National Institutes of Health I National Library of Medicine

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

Additional NIH Notices of Special Interest and Funding Opportunities that were released in this week's NIH Guide for Grants and Contracts are included in the InfoEd tables below.
# SPIN Table 1 - Summary

Links below connect to more detailed information in Table 2.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>043741</td>
<td>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme</td>
<td>International AIDS Society</td>
<td></td>
<td>01-Oct-2020</td>
<td>300,000 USD</td>
</tr>
<tr>
<td>097151</td>
<td>RFA-OD-20-014 -- Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>RFA-OD-20-014</td>
<td>21-Aug-2020 [Optional] [LOI/Pre-App]</td>
<td>600,000 USD</td>
</tr>
<tr>
<td>097596</td>
<td>Understanding the Factors that Affect the Detection and Variability of SARS-CoV-2 in Wastewater</td>
<td>Water Research Foundation</td>
<td></td>
<td>10-Aug-2020</td>
<td>300,000 USD</td>
</tr>
<tr>
<td>097610</td>
<td>J-PAL Africa’s Digital Identification and Finance Initiative (DigiFI Africa)</td>
<td>Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>250,000 USD</td>
</tr>
<tr>
<td>097626</td>
<td>J-PAL North America Short Term Research Management Program (STReaM)</td>
<td>Poverty Action Lab (J-PAL Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097627</td>
<td>J-PAL North America US Health Care Delivery Initiative (HCDI)</td>
<td>Poverty Action Lab (J-PAL Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097665</td>
<td>Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)</td>
<td>National Science Foundation</td>
<td>NSF 20-105</td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097716</td>
<td>COVID-19 Private Sector Engagement &amp; Partnership Fund RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to</td>
<td>Department of State</td>
<td>SFOP0007088</td>
<td>28-May-2021</td>
<td>1,000,000 USD</td>
</tr>
<tr>
<td>097717</td>
<td></td>
<td>National Institutes of</td>
<td>RFA-TR-20-003</td>
<td>Continuous</td>
<td>9,000,000 USD</td>
</tr>
<tr>
<td>FDA Reference Number</td>
<td>Title</td>
<td>Agency</td>
<td>Due Date</td>
<td>Amount</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>097747</td>
<td>Treat COVID-19 Sequelae (U01 Clinical Trial Required)</td>
<td>Health/DHHS</td>
<td>15-Aug-2020</td>
<td>4,000,000 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-015 -- Emergency Awards: RADx-rad Wastewater Detection</td>
<td></td>
<td>[Optional]</td>
<td>[LOI/Pre-App]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>veillance Methods for High Risk Clustered Populations (R01 Clinical</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trial Optional)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-017 -- Emergency Awards RADx-RAD: Screening for COVID-19 by</td>
<td>National Institutes of</td>
<td>18-Aug-2020</td>
<td>Not Specified</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technologies Towards Multi-Parametric and Integrated Approaches for</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SARS-CoV-2 (U18 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-019 -- Emergency Awards: RADx-rad Data Coordination Center</td>
<td>National Institutes of</td>
<td>31-Aug-2020</td>
<td>16,000,000 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(DCC) (U24 Clinical Trial Not Allowed)</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-020 -- Emergency Awards RADx-RAD: Novel Biosensing for</td>
<td>National Institutes of</td>
<td>18-Aug-2020</td>
<td>1,710,531 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cavity (R44 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-021 -- Emergency Awards RADx-RAD: Novel Biosensing for</td>
<td>National Institutes of</td>
<td>18-Aug-2020</td>
<td>1,710,531 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cavity (Fast-Track STTR Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>097784</td>
<td>RFA-OD-20-022 -- Emergency Awards: Chemosensory Testing as a COVID-19</td>
<td>National Institutes of</td>
<td>15-Sep-2020</td>
<td>750,000 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening Tool (U01 Clinical Trial Optional)</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RFA-OD-20-023 -- Emergency Awards: RADx-rad Predicting Viral-Associated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammatory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>097792</td>
<td>RFA-OD-20-024 -- Emergency Awards: RADx-rad Predicting Viral-Associated</td>
<td>National Institutes of</td>
<td>31-Aug-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammatory</td>
<td>Health/DHHS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>043741</td>
<td>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme</td>
<td>International AIDS Society</td>
<td></td>
<td>01-Oct-2020</td>
<td>300,000 USD</td>
</tr>
</tbody>
</table>

Contact Name
Contact Telephone +41-(0)22-7 100 800
Contact Email cipher@iasociety.org
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 01-Oct-2020

Synopsis

The CIPHER Grant Programme directly supports the development of early-stage investigators, awarding up to US$150,000 for up to two years to address research gaps in paediatric and adolescent HIV in resource-limited settings. The purpose of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme is to fund research projects with the potential to address critical research questions that remain unanswered in the global response in order to inform policy change and ensure better outcomes in infants, children and adolescents living with and affected by HIV in resource-limited settings. Designed for early-stage investigators, a key aim of the programme is to build research capacity within resource-limited settings by fostering the next generation of investigators in paediatric and adolescent HIV. It is intended to attract young investigators from inside and outside the field of HIV. This will help encourage innovative ideas and lead to the design of evidence-based approaches and interventions to overcome major obstacles in the field.
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Research projects may need to adapt quickly in the context of COVID-19. The Short Term Research Management program (STReaM) makes experienced research management staff available to help researchers in the North America region navigate these challenges. STReaM will continue to accept requests for support through its regular application process. The team can offer hands-on support to help think through challenging obstacles, such as impacts to timelines, adapting to virtual research methods, and navigating difficult conversations with stakeholders. Researchers conducting projects in the North America region are invited to request this support, regardless of the project phase.

As always, HCDI is open to receiving off-cycle proposals on time-sensitive topics. HCDI welcomes proposals that focus on producing evidence that North America decision-makers can act upon promptly to respond to the current crisis. Please note that the sponsor will not accept human subjects research requiring in-person interactions with subjects.

Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)
With this Dear Colleague Letter (DCL), the sponsor highlights the interest of existing programs in the Directorate for Biological Sciences (BIO) and the Directorate for Engineering (ENG) in interdisciplinary research for the development of novel biological platforms that are capable of sensing and responding to emerging infectious agents. The mechanism of sensing should be adaptable and or evolvable such that the sentinel cells, or other appropriate biotechnology solutions, are robust to a range of emergent threats, and/or can easily be reprogrammed and deployed once a new threat is identified. The platform's response should be one or more of the following: alert the user, destroy the threat, protect the host, initiate an immune response or other strategies that would ensure mitigation of the threat. Sentinel cells and organisms that detect and respond to infectious agents with expanding footprints in a host population or expanding host ranges are of particular interest, as the early detection of these infectious agents might have value in preventing future pandemics. In addition, fundamental science and technology that would lead to the development of the envisioned sentinel cells and organisms are also of interest. Investigators are encouraged not to be limited in their approach, but to think broadly about innovations leveraging biology and engineering to advance adaptable detection of emerging biological threats.

097716 COVID-19 Private Sector Engagement & Partnership Fund
Department of State SFOP0007088 28-May-2021 1,000,000 USD
Contact Name
Contact Telephone
Contact Email PPPCOVID19Fund@state.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 28-May-2021
The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards. Through this APS, the Department of State (DOS) announces its desire to engage private sector partners to expand and amplify the Department’s COVID-19 response. The Fund seeks to support private sector interventions and build upon private sector investments in response to the virus.

097717 RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
National Institutes of Health/DHHS RFA-TR-20-003 Continuous 9,000,000 USD
Contact Name
Contact Telephone
The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Synopsis

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude cheaper and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to increase sensitivity and to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models. The funding for this initiative is provided from the Paycheck Protection Program.
RFA-OD-20-016 -- Emergency Awards: RADx-RAD Multimodal COVID-19 Surveillance Methods for High Risk Clustered Populations (R01 Clinical Trial Optional)

Contact Name: Elena Koustova, PhD, MBA
Contact Telephone: 301-496-8768
Contact Email: elena.koustova@nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. The funding for this initiative is provided form the Paycheck Protection Program and Health Care Enhancement Act, 2020.
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings. This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

RFA-OD-20-018 -- Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

RFA-OD-20-019 -- Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

31-Aug-2020 [Optional] USD 16,000,000

Contact Name: Valerie Florance, PhD
Contact Telephone: 301-496-4621
Contact Email: florancev@mail.nih.gov

Synopsis

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

RFA-OD-20-020 -- Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

18-Aug-2020 [Optional] USD 1,710,531

Contact Name: Orlando Lopez, Ph.D.
Contact Telephone: 301-402-4243
Contact Email: orlando.lopez@nih.gov
RFA-OD-20-021 -- Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)

National Institutes of Health/DHHS

RFA-OD-20-021 18-Aug-2020 [Optional][LOI/Pre-App] 1,710,531 USD

Contact Name Orlando Lopez, Ph.D.
Contact Telephone 301-402-4243
Contact Email orlando.lopez@nih.gov

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

RFA-OD-20-022 -- Emergency

National Institutes of Health/DHHS

RFA-OD-20-022 18-Aug-2020 [Optional][LOI/Pre-App], 18-Sep-2020

Contact Name Orlando Lopez, Ph.D.
Contact Telephone 301-402-4243
Contact Email orlando.lopez@nih.gov

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)

Institutes of Health/DHHS

RFA-OD-20-022

15-Sep-2020

750,000 USD

Contact Name Susan Sullivan, Ph.D.

Contact Telephone 301-451-3841

Contact Email sullivas@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 15-Sep-2020

Synopsis

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

RFA-OD-20-023 -- Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)

National Institutes of Health/DHHS

RFA-OD-20-023

31-Aug-2020 [Optional] [LOI/Pre-App]

Not Specified

Contact Name Bill G. Kapogiannis, MD

Contact Telephone 301-402-0698

Contact Email kapogiannisb@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 31-Aug-2020 [Optional][LOI/Pre-App], 30-Sep-2020

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA seeks to support innovative research to develop
## Synopsis

Novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS-CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

### Notice of Special Interest (NOSI):

**Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool**

**National Institutes of Health/DHHS**

**NOT-OD-20-152**

**15-Sep-2020**

**Not Specified**

**Contact Name** Susan Sullivan, Ph.D.

**Contact Telephone** 301-451-3841

**Contact Email** sullivas@nidcd.nih.gov

**Sponsor Website** [Link to program URL](#)

**Deadline Dates (ALL)** 15-Sep-2020

NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities
Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below is a COVID-19 funding opportunity recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>097934</td>
<td>Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations</td>
<td>National Institute on Minority Health and Health Disparities/NIH/DHHS</td>
<td>NOT-MD-20-026</td>
<td>05-Oct-2020</td>
</tr>
</tbody>
</table>

Contact Name: Larissa Aviles-Santa, MD, MPH
Contact Telephone: 301-827-6924
Contact Email: avilessanta1@nih.gov
The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.

FSMB Foundation COVID-19 State Response Grants

FSMB Foundation

Federation of State Medical Boards Foundation

01-Oct-2020 [LOI/Pre-App]

25,000 USD

FSMBFoundation@fsmb.org

FSMB Foundation COVID-19 Grants are designed to offer state medical and osteopathic boards and other health care organizations funding support for the study of state responses to the COVID-19 pandemic. The long-term goal of the program is to support the development and implementation of sustainable models and policies that can guide state preparedness and responses to similar emergencies in the future, as well as their capacity for recovery planning.

SMARTSTM funding alerts are a service of InfoEd Global's SPIN™ funding opportunities
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office
Weekly NIH Funding Opportunities and Notices for August 14, 2020

### General Notices

- **Notice of Early Expiration of NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-066)**
  National Institute of Allergy and Infectious Diseases

### Notice of Changes to Funding Opportunities

- **NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations) (NOT-HL-20-806)**
  National Heart, Lung, and Blood Institute

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see [https://grants.nih.gov/grants-guide/rss_info.htm](https://grants.nih.gov/grants-guide/rss_info.htm) for details.

Additional NIH Notices of Special Interest and Funding Opportunities that were released in this week's NIH Guide for Grants and Contracts are included in the InfoEd tables below.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Deadline</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>098050</td>
<td>Ignacio H. de Larramendi Research Grants</td>
<td>Fundación MAPFRE</td>
<td>30-Oct-2020</td>
<td>35,400 USD</td>
</tr>
</tbody>
</table>

**Contact Name**

- **Contact Telephone** (+34) 91.581.23.45
- **Contact Email** [salud@fundacionmapfre.org](mailto:salud@fundacionmapfre.org)
- **Sponsor Website** [Link to sponsor website](https://fundacionmapfre.org)
- **Program URL** [Link to program URL](https://fundacionmapfre.org)
- **Deadline Dates (ALL)** 30-Oct-2020

**Synopsis**

In the 2020 call, the sponsor is awarding Research Grants totaling 240,000 Euros to provide financial support for undertaking research projects in areas of Health Promotion.

[Notice of Special Interest (NOSI): Availability of](https://grants.nih.gov/grants-guide/) National Institute of NOT-
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>098066</td>
<td>Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2</td>
<td>Allergy and Infectious Diseases/NIH/DHHS</td>
<td>Link to program URL</td>
<td>14-Sep-2020, 14-Oct-2020, 14-Nov-2020, 14-Dec-2020, 14-Jan-2021, 14-Feb-2021, 14-Mar-2021, 14-Apr-2021, 14-May-2021, 14-Jun-2021, 14-Jul-2021, 14-Aug-2021, 14-Sep-2021</td>
<td>This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19 therapeutic approaches to treat COVID-19</td>
</tr>
<tr>
<td>098071</td>
<td>Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities</td>
<td>National Institutes of Health/DHHS</td>
<td>Link to program URL</td>
<td>05-Oct-2020, 05-Feb-2021, 05-Jun-2021, 05-Oct-2021, 05-Feb-2022, 05-Jun-2022, 05-Oct-2022, 05-Feb-2023</td>
<td>The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.</td>
</tr>
</tbody>
</table>

**SMARTSTM** funding alerts are a service of **InfoEd Global**'s **SPINTM** funding opportunities.

---

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

From: Table of Contents for the NIH Guide for Grants & Contracts On Behalf Of Guide TOC
Sent: Friday, August 21, 2020 3:00 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Funding Opportunities and Notices for 08-21-2020 (The NIH Guide TOC)
NIH Guide for Grants and Contracts (Web Version)

Weekly NIH Funding Opportunities and Notices for August 21, 2020

Notice of Changes to Funding Opportunities

- Notice of Participation in RFA-OD-20-023, "Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)" (NOT-TR-20-034)
  National Center for Advancing Translational Sciences

Funding Opportunities

- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
  National Institute on Drug Abuse
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): May 17, 2021, May 17, 2022, May 17, 2023

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

Additional NIH Notices of Special Interest and Funding Opportunities that were released in this week's NIH Guide for Grants and Contracts are included in the InfoEd tables below.
<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>078460</td>
<td>Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PAR-19-064</td>
<td>06-Oct-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong> Marsha F. Lopez, PhD, MHS</td>
<td><strong>Contact Telephone</strong> 301-443-6504</td>
<td><strong>Contact Email</strong> <a href="mailto:lopezmar@mail.nih.gov">lopezmar@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsor Website</strong></td>
<td><strong>Program URL</strong></td>
<td><strong>Deadline Dates (ALL)</strong> 06-Oct-2020 , 08-Feb-2021 , 08-Jun-2021 , 08-Oct-2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong> This Funding Opportunity Announcement (FOA) will support pilot,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>feasibility or exploratory research in 7 priority areas in substance use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>epidemiology, prevention, and health services, including: 1) responses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>to sudden and severe emerging drug issues (e.g. the ability to look</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in a particular community); 2) responses to emerging marijuana trends and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>topics related to the shifting policy landscape; 3) responses to unexpected</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>and time-sensitive prescription drug abuse research opportunities (e.g., new</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>state or local efforts); 4) responses to unexpected and time-sensitive medical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>system issues (e.g. opportunities to understand addiction services in the</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>evolving health care system); 5) responses to unexpected and time-sensitive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>criminal or juvenile justice opportunities (e.g. new system and/or structural</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>level changes) that relate to drug abuse and access and provision of health</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>care service; 6) partnerships between researchers and state or local</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>organizations to support the evaluation of new local policies, programs, or</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>practices in response to public health emergencies (e.g., the opioid crisis);</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7) research collecting and examining data on the risks and outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>associated with substance use and COVID-19 infection in the general population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>and among underserved populations, such as racial, ethnic and gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>minorities, individuals with low socioeconomic status, and those who are</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>incarcerated or homeless. It should be clear that the knowledge gained from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>the proposed study is time-sensitive and that an expedited rapid review and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>funding are required in order for the scientific question to be answered (i.e.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>an imminent policy change will not allow for standard review and funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>timeline).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>098289</td>
<td>Fast Track Access</td>
<td>Euro-Bioimaging</td>
<td>Continuous</td>
<td>Not Specified</td>
<td></td>
</tr>
</tbody>
</table>
Technologies for COVID-19 Research Projects

This opportunity offers access to biomedical imaging technologies to scientists who have COVID-19 related research projects that need imaging resources. Euro-BioImaging can facilitate access to 40+ biological and biomedical imaging technologies in one of 21 Nodes. Nodes are internationally renowned imaging facilities - located across 8 countries and the European Molecular Biology Laboratory, EMBL.

**Epilepsy Research Continuity Find (ERCF)**

<table>
<thead>
<tr>
<th>Sponsor Name</th>
<th>Citizens United for Research in Epilepsy</th>
<th>31-Aug-2020</th>
<th>15,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>312-255-1801</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Research@CUREepilepsy.org">Research@CUREepilepsy.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>31-Aug-2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CURE awards grants for novel research projects that address finding the cures for epilepsy and address the goal of “no seizures, no side-effects.” The Epilepsy Research Continuity Find (ERCF) will provide reimbursements of up to $15,000 for research related expenses incurred as a result of institutional shutdowns during the COVID-19 pandemic and for which institutional support was not available or provided.

SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities
Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN. The first table of InfoEd funding opps is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

**SPIN Table 1 - Summary**

*Links below connect to more detailed information in Table 2.*

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>040671</td>
<td>Specific Priorities Research Grants</td>
<td>WorkSafeBC</td>
<td>Association for</td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Pilot Grant for Basic</td>
<td></td>
<td></td>
<td>09-Oct-2020</td>
<td></td>
</tr>
</tbody>
</table>
SPIN Table 2 - Detailed Information

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>040671</td>
<td>Specific Priorities Research Grants</td>
<td>WorkSafeBC</td>
<td></td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name
Contact Telephone  604-244-6300
Contact Email resquery@worksafebc.com
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 31-Oct-2020

Synopsis
WorkSafeBC’s Research Services funds are designed to address operational need and help answer key questions in occupational health and safety and workers’ compensation. These grants support short-term, primary and secondary research of immediate relevance. This research gives us the strongest scientific evidence to use when developing policy and practice.

| 065049  | Pilot Grant for Basic Science Research             | Association for Frontotemporal Degeneration |                | 09-Oct-2020   | 60,000 USD    |

Contact Name Debra Niehoff, PhD, Research Manager
Contact Telephone 267-758-8654
Contact Email dniehoff@theaftd.org
### Synopsis

AFTD Pilot Grants provide seed funding for innovative research with the potential to improve the understanding and treatment of frontotemporal degeneration (FTD) across the full spectrum of FTD disorders: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS. Pilot Grant-funded projects are intended to generate data that will support follow-on funding applications to the National Institutes of Health or other public or private agencies.

### Fellowship Program

**IBSA Foundation for Scientific Research**

- **ID**: 098691
- **Title**: Fellowship Program
- **Contact Name**: IBSA Foundation
- **Contact Telephone**: +41 58 360 10 00
- **Contact Email**: info@ibsafoundation.org
- **Deadline**: 31-Dec-2020
- **Funding**: 35,700 USD

**Synopsis**

The IBSA Foundation provides fellowships to young researchers under the age of 40, from Universities and Institutes around the world, who have distinguished themselves for their skills and have ongoing projects of particular relevance in four specific fields of medical discipline – Dermatology, Endocrinology, Fertility, Orthopaedics-Rheumatology and Pain Medicine – to which is added the Special Edition which changes every year.

### NIOSH Centers of Excellence for Total Worker Health® (U19)

**National Institute for Occupational Safety & Health/CDC/DHHS**

- **ID**: 098891
- **Title**: NIOSH Centers of Excellence for Total Worker Health® (U19)
- **Contact Name**: Maria Lioce, MD
- **Contact Telephone**: 404-498-2575
- **Contact Email**: MLioce@cdc.gov
- **Funding**: 7,000,000 USD

**Synopsis**

NIOSH/CDC invites applications for the NIOSH Centers of Excellence for Total Worker Health (TWH). The purpose of this FOA is to solicit meritorious applications for Centers of Excellence for TWH to develop and conduct a broad range of multidisciplinary research, intervention, outreach and education, and evaluation activities that advance the overall safety, health, and well-being of the diverse population of workers in our nation. Center structure should
take advantage of diverse scientific resources and focus on local, regional, or national worker safety and health issues. Centers should emphasize creating and implementing evidence-based solutions to address evolving challenges and opportunities related to worker safety, mental and physical health, and well-being. Collaborations in partnership with academic institutions, nonprofit organizations, and other groups focused on occupational safety and health are expected. Applicants must concisely describe the occupational health burden within their service area and directly link research and outreach activities to help alleviate the burden. Applicants should also clearly articulate the anticipated impacts of the proposed work, both during the project period and beyond.

**Junior Faculty Research Grants for the Study of Lung Cancer and COVID-19 Infection**

International Lung Cancer Foundation

15-Sep-2020 50,000 USD

Contact Name
Contact Telephone 1-720-598-1952
Contact Email foundation@iaslc.org
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 15-Sep-2020

The purpose of this program is to fund groundbreaking research related to COVID-19 infected lung cancer patients. The intent of the support is to allow junior faculty researchers, as defined as fewer than 7 years in a faculty position after training, to obtain preliminary data that will enable them to successfully compete for national peer-reviewed grant support.

**Diversity and Inclusion Health Equity Research Grant**

Foundation for Women's Cancer

21-Sep-2020 75,000 USD [LOI/Pre-App]

Contact Name
Contact Telephone 312-578-1439
Contact Email research@sgo.org
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 21-Sep-2020 [LOI/Pre-App], 21-Dec-2020

Research among diverse populations has demonstrated disparities in treatment outcomes, access to care, genetic testing rates, and disease survival across many diseases. This new Diversity and Health Equity Research Grant is a one-year project where the funding is available for two $75,000 Research grants.